TPD52L2 Antibody


PACO20740



Product Information Size: **Protein Background:** 50ul E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of target proteins. E3 ubiquitin ligases accept ubiquitin from an E2 **Reactivity:** ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Mediates E3 ubiquitin ligase activity either through Human, Mouse direct binding to substrates or by functioning as the essential RING domain subunit of Source: larger E3 complexes. Triggers the ubiquitin-mediated degradation of many substrates, including proteins involved in transcription regulation (POU2AF1, PML, NCOR1), a cell Rabbit surface receptor (DCC), an antiapoptotic protein (BAG1), and a protein involved in synaptic vesicle function in neurons (SYP). Mediates ubiquitination and proteasomal **Isotype:** degradation of DYRK2 in response to hypoxia. It is thereby involved in apoptosis, tumor lgG suppression, cell cycle, transcription and signaling processes. Has some overlapping function with SIAH1. Triggers the ubiquitin-mediated degradation of TRAF2, whereas **Applications:** SIAH1 does not. ELISA, WB, IHC Gene ID: **Recommended dilutions:** TPD52L2 ELISA:1:2000-1:5000, WB:1:500-1:2000, Uniprot IHC:1:25-1:100 O43399 Synonyms: tumor protein D52-like 2 Immunogen: Synthetic peptide of human TPD52L2.

Storage:

-20° C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol



The image on the left is immunohistochemistry of paraffin-embedded Human breast cancer tissue using PACO20740(TPD52L2 Antibody) at dilution 1/35, on the right is treated with synthetic peptide. (Original magnification: x—200).

Gel: 8%SDS-PAGE, Lysate: 40 ug, Lane 1-5: 293T cells, MCF7 cells, mouse brain tissue, K562 cells, mouse bladder tissue, Primary antibody: PACO20740(TPD52L2 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds.

The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using PACO20740(TPD52L2 Antibody) at dilution 1/35, on the right is treated with synthetic peptide. (Original magnification: x—200).